anthydoc

Less than two months after OXB revealed a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy manufacturer has purchased a viral vector plant in North Carolina

The company will work with new local contract manufacturers in India to boost supply of its key medicines.

The FDA unveiled a new pilot program that aims to speed up review times for generic drugmakers who test and manufacture their products in the U.S. Separately, the agency met with industry

The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.

Vaxcyte is paying Thermo Fisher Scientific up to $1 billion to access vaccine fill-finish capacity at the CDMO’s production facility in Greenville, North Carolina. Vaxcyte positioned the deal as a “long-term U.S.

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B financing round that will be used to expand the company’s DNA synthesis production capacity in the U.S.